SCHEMBL24709353

SCHEMBL24709353

O=c1n(CCCCc2ccccc2)c2ccc(Cl)cc2n1C1CCN(CCCCc2ccccc2)CC1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CACNA1G O43497 4/20 0.78
▸ CACNA1H O95180 4/20 0.78
▸ DRD2 P14416 7/20 0.53
▸ DRD3 P35462 6/20 0.53
▸ SLC6A4 P31645 4/20 0.53
▸ CYP1A2 P05177 3/20 0.53
▸ CYP2D6 P10635 3/20 0.53
▸ HRH1 P35367 3/20 0.53
▸ HTR2B P41595 3/20 0.53
▸ HTR1A P08908 3/20 0.53
▸ USP2 O75604 2/20 0.53
▸ MEN1 O00255 2/20 0.53
▸ CYP3A4 P08684 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ HTR2A P28223 2/20 0.53
▸ SLC22A2 O15244 1/20 0.53
▸ NR1I2 O75469 1/20 0.53
▸ GMNN O75496 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ GLA P06280 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24708751 0.96 CACNA1G (0.78) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24709338 0.91 CACNA1G (0.87) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24708732 0.91 CACNA1G (0.87) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL31000419 0.90 CACNA1G (0.82) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24709126 0.90 CACNA1G (0.82) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24708728 0.90 CACNA1G (0.82) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL27194843 0.89 CACNA1G (0.66) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24708718 0.88 CACNA1G (0.83) CACNA1GCACNA1HDRD2DRD3SLC6A4
SCHEMBL24708724 0.88 CACNA1G (1.00) CACNA1GCACNA1HDRD2DRD3CYP1A2
SCHEMBL30079694 0.88 CACNA1G (1.00) CACNA1GCACNA1HDRD2DRD3CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2024-08-29 — — US disclosed
EP-4353713-A1 T-TYPE CALCIUM CHANNEL BLOCKER Kinki University (JP) 2024-04-17 — — EP disclosed
WO-2022260016-A1 T-TYPE CALCIUM CHANNEL BLOCKER 学校法人近畿大学 2022-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287019-A1 T-TYPE CALCIUM CHANNEL BLOCKER CACNA1G, CACNA1I, CACNA1H CACNA1G 1/4885CACNA1H 3/4885DRD2 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback